SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mind Medicine (MindMed) Inc. (MNMD) , forward earnings yield 4.80%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($16.00, 22.7%).
- Forward P/E 20.8
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $16.00 (-22.7% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 32/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MNMD
Valuation Multiples
P/E (TTM)0.0
Forward P/E20.8
PEG Ratio0.11
Forward PEG0.11
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.06
Forward EPS (Est.)$0.99
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield4.80%
Dividend Yield0.00%
Analyst Target$16.00 (-22.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-2.24 |
$0.00 |
$-179.9K |
- |
| 2017 |
$-4.85 |
$0.00 |
$-1.23M |
- |
| 2018 |
$-2.74 |
$0.00 |
$-857.94K |
- |
| 2019 |
$-2.94 |
$0.00 |
$-1.12M |
- |
| 2020 |
$-1.92 |
$0.00 |
$-34.1M |
- |
| 2021 |
$-3.40 |
$0.00 |
$-93.04M |
- |
| 2022 |
$-1.53 |
$0.00 |
$-47.26M |
- |
| 2023 |
$-2.44 |
$0.00 |
$-95.73M |
- |
| 2024 |
$-0.15 |
$0.00 |
$-108.68M |
- |
| 2025 |
$-2.06 |
$0.00 |
$-183.79M |
- |
